

REVIEW ARTICLE

From laboratory to computer models: Enhancing coumarin discovery through interdisciplinary research

Marwa Mohammed Alshaher, Yasser Fakri Mustafa*

Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq

*Corresponding author: Yasser Fakri Mustafa, Dr.yassermustafa@uomosul.edu.iq, <https://orcid.org/0000-0002-0926-7428>

ABSTRACT

Coumarin-derived compounds have garnered extensive interest due to their diverse applications in medicinal chemistry, pharmacology, food, and cosmetics. There are pros and cons to both in vitro and in silico methods used in coumarin-based research. The focus is on their roles, pros, and cons in finding out the biomedical properties of these compounds. In vitro studies, conducted in controlled environments, enable detailed investigations into cellular mechanisms, enzyme interactions, and cytotoxic effects. These studies are valuable for elucidating coumarin's biological activity and therapeutic potential. Although these studies are accurate, morally acceptable, and repeatable, their inability to fully replicate complex biological systems necessitates extrapolation to real-life situations. In contrast, in silico studies leverage computational tools to model molecular interactions, predict pharmacokinetic behaviors, and simulate biological pathways. These techniques are time- and cost-efficient, capable of high-throughput screening, and useful for hypothesis generation. However, their reliability depends on the accuracy of input data and assumptions, which can limit their predictive power in real-world scenarios. Integrating these two study types provides a synergistic framework that enhances coumarin-based research. In silico models can guide the design of experiments, while in vitro assays validate computational predictions. Emerging technologies, such as machine learning, organ-on-a-chip systems, and 3D cell cultures, promise to further refine this integration, enabling faster, more accurate, and ethical research. We conducted an investigation and a literature review, utilizing PubMed data and limiting the publication period from 2000 to mid-2024. This study demonstrates the effective combination of in vitro and in silico methods to advance coumarin-based research and unlock its full therapeutic potential.

Keywords: coumarins; in vitro, in silico; effective coupling

ARTICLE INFO

Received: 7 February 2025

Accepted: 18 February 2025

Available online: 21 February 2025

COPYRIGHT

Copyright © 2025 by author(s).

Applied Chemical Engineering is published by Arts and Science Press Pte. Ltd. This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY 4.0).

<https://creativecommons.org/licenses/by/4.0/>

1. Introduction

Coumarin-based compounds (CBCs) are a family of natural and synthetic compounds with a coumarin backbone in their frameworks^[1]. Their wide use field includes medicinal chemistry, pharmacology, the food industry, spices, perfumes, and cosmetics. Due to the widespread use and potential applications of CBCs, the interest in these molecules has increased exponentially among many researchers^[2]. In vitro and in silico studies have proven to be useful tools for understanding the properties of a wide range of CBCs. Furthermore, the convergence of in vitro and in silico studies in current research presents a promising alternative^[3].

Considering all these factors, we concentrated on investigating the properties of CBCs through in vitro and in silico studies, discussing their potential as therapeutic candidates. We also attempted to compare the research methods, highlighting the advantages and disadvantages of both in silico and in vitro studies with respect to these properties.

Based on the above observation, the objectives of this study are to dissect these two study types to show the advantages and disadvantages of each study method in the investigation of the CBCs' bioactivity. The subject's complexity necessitates the documentation of each study in separate sections. We found no literature to compare the two studies conducted on CBCs, despite a literature review revealing the relationship between these two important studies from a variety of molecular perspectives.

2. Historical perspective of coumarin-based research

In 1830, Vogel of Göttingen obtained coumarin from tonka beans and established its melting point as 68°C, while in 1868, Petrou isolated this phytochemical from a *Melilotus coerulea* mill. In 1886, V. P. Krymberg determined the structure of coumarin, and in the same year, A. Pictet and F. Myer described the synthesis and chemical properties of "synthetic" or "artificial" coumarin^[4,5]. On the other hand, Idris Davulcu was the first man who isolated coumarin from *Thymus vulgaris*^[6,7]. Therefore, using currently developed ultramodern techniques, a wide range of promising and potentially beneficial activities are attributed to this single chemically heterocyclic compound. Historically, coumarin played a significant role in various cosmetics like bathing powders, toilet vinegar for hair washing, and Eau de Cologne^[8,9]. Within a decade, Wittstein discovered coumarin and introduced it to the scientific world as a new perfumed compound. In retrospect, scientists appreciate that coumarin's field of action extends beyond this. Decidedly significant hostility was also shown in agricultural chemical activities when W. Brode assessed the moth-resistant property of coumarin^[10,11].

Researchers have conducted extensive studies on the synthetic route for the coumarin backbone. Also, they have determined the overall percentage yield of coumarin based on these reactions. Many coumarin-related publications also discuss the use of synthetic coumarin as a rigid framework for the development and design of biological activities^[12,13]. The plant families Asperulaceae and Rubiaceae largely distribute CBCs, and scientists have identified over 130 natural CBCs from sixty related plant species, primarily in the genera *Galium* and *Asperula*^[14,15]. Interestingly, the use of coumarin has not decreased in traditional medicine, and there has been a growing fascination with CBCs due to the extensive number of research studies conducted^[16,17]. In fact, the research on these compounds has broken all records in becoming a standard pharmacological search tool, with more than 18,000 published articles since 1978^[18,19]. Today, the increasing availability of new data has led to the writing of several reviews on coumarin, CBCs, and sarcomeres^[20–22]. Researchers are reviewing coumarin itself, not its derivatives, based on its combined applications of in vivo and in vitro investigations^[23,24]. Furthermore, at the beginning of the second decade of the 21st century, research on a small, chemically heterocyclic compound like coumarin has become a necessity, and this may be one of the few results available based on both historical and backup data^[25–27]. Regarding many aspects, **Table 1** provides a comparison between these two types of investigations.

Table 1. Comparison of in vitro and in silico studies: Key aspects, tools, and applications.

Aspect	In vitro studies	Ref.	In silico studies	Ref.
Definition	Experiments conducted outside a living organism, typically in controlled lab environments (e.g., petri dishes and test tubes)	[28]	Studies conducted using computer simulations, algorithms, or computational models	[29]
Primary tools	Cell cultures, biochemical assays, microfluidics, and laboratory equipment	[30]	Computational models, bioinformatics tools, machine learning, and databases	[31]
Applications	Drug efficacy testing, toxicity screening, molecular interactions, and biological pathway analysis	[32]	Virtual screening, predicting molecular properties, modeling biological systems	[33]
Accuracy	Provides direct biological relevance but may not fully mimic physiological conditions	[34]	Dependent on the quality of the data and algorithms; results may lack experimental realism	[35]

Aspect	In vitro studies	Ref.	In silico studies	Ref.
Speed	Slower due to manual experimental procedures and cell culture growth times	[36]	Faster, as simulations and analyses can often be automated and run on powerful computers	[37]
Cost	High, due to reagents, equipment, and labor costs	[38]	Typically lower, requiring computational infrastructure and software	[39]
Ethical concerns	May involve the use of animal or human-derived cells, raising ethical questions	[40]	No ethical concerns related to direct experimentation; relies on existing dataset	[41]
Scalability	Limited scalability due to physical constraints in lab setups		Highly scalable, as multiple simulations can run simultaneously	[42]
Limitations	- Limited ability to mimic whole-organism complexity - Time- and resource-intensive	[43]	- Results depend on the quality of input data - Simplifications may overlook key biological nuances	[44]
Complementary role	Provides validation of hypotheses generated by in silico studies	[45]	Generates hypotheses and narrows down targets for in vitro and in vivo validation	[46]

Table 1. (Continued)

We looked at every publication from 2000 to the middle of 2024 and found that 4854 papers talk about CBCs and their in vitro research, 505 articles talk about these compounds and their in silico research, and 258 articles link CBCs to both types of analysis. These figures demonstrate that when assessing the biomedical characteristics of CBCs, in vitro research takes precedence over in silico studies. **Figure 1** shows how few research studies have used CBCs and combined the findings of these two kinds of investigations. This is why we did this review study to highlight the importance of in vitro-in silico CBC evaluation and encourage more research.




Figure 1. Co-occurrence network relationship between CBCs, in vitro, and in silico studies.

3. Fundamentals of in vitro studies

The study of biological phenomena resides on two principles: gaining insights reduces risks, and designing tests for prediction makes it possible to model the behavior of whole living beings^[47,48]. In this case, researchers conduct an in vitro study using freshly excised tissue from a whole animal or organ^[49,50]. They also design in vitro studies to thoroughly examine a single biological process, both empirically and statistically, while minimizing noise^[51,52]. Basically, in vitro studies help us understand, at the cellular or tissue level, the mechanism by which that organism achieves a certain end^[53,54]. One of the three most commonly used in vitro methods for research involves designing an experiment to extend data to tissues or the entire biological level, thereby enabling researchers to answer meaningful questions^[55,56].

One of the advantages of using in vitro methods is that most biological agents can tolerate a wide range of culture conditions; therefore, it is possible to design experiments to confirm previous in vivo results. Research advancements can occasionally prompt a return to in vitro studies for the purpose of conducting these experiments^[57,58]. Rather than discarding all the lessons learned from the in vitro study, we could save time and expense by using it to inform opinions or future research, potentially leading to different conclusions. Among the three areas of applications within coumarin-based research, most in vitro studies fall into one category that discussed above^[59,60].

The next subheads report examples of these studies and their underlying methodologies, illustrating the current implementation of these methodologies in coumarin-based research. However, while the information provided is not exhaustive, it also illustrates the variety of methods and models employed in today's coumarin-based research. The methodologies used in the in vitro proof of concept and first exploratory studies in humans in phase I and phase II studies are presented as examples: these types of studies and their underlying methodologies are commonly employed in therapeutic research.

3.1. Types of in vitro studies

Several types of in vitro studies exist, including the use of established cell lines or primary cells, as well as organotypic, organ-on-a-chip, or organoid studies. These studies concentrate on organs with a breed-like structure and cells whose culture typically lasts no more than 100 days^[61,62]. Biochemical tests also check the activity or selectivity of different P450 isoforms and other enzymes that break down xenobiotics^[63,64]. Based on experimental phenomena, in vitro studies primarily focus on three areas of pharmaceutical-biological research related to CBCs. 1) Investigating the mechanisms of cytotoxic and tumor-suppressive effects^[65,66]; 2) Examining the interactions between cytochrome oxidase^[67,68]; and 3) Investigating the anti-adherent and anti-infectious effects^[69,70].

We identified 23 in vitro studies in the field of coumarin metabolism. The most important research questions in this area are how CYP2A6, 2B6, 2C8, 2C9, 2E1, and 3A4 can prevent CBCs from functioning abroad. The other question is how well or selectively can enzymes demethylate a certain pure compound or its group of non-oxygenated, monomethoxylated, dimethoxylated, and trimethoxylated compounds?^[71,72] The enzymes 7-ethoxyresorufin O-deethylase, 7-methoxyresorufin O-demethylase, 7-pentoxyresorufin O-depentylation, and 7-benzyloxyresorufin O-debenzylation are CYP-specific and ultrapotent; they are reversible, with 1:1 competitive and mixed inhibition^[73,74].

The versatility and variability of in vitro study types in coumarin-based research differ in certain aspects from one to the other. It can adopt the in vitro study in its most extreme form if it's feasible or strictly necessary^[75,76]. Otherwise, it may choose the most suitable and/or available in vitro experiment. This experiment has pros and cons, with its lack of relevance being the most contentious^[77,78]. It is true that no individual or meta-analysis of in vitro experiments provides statistically or practically sufficient evidence. However, multidirectional evidence from these experiment that adhere to strict methodological guidelines not

only enhances our understanding of the compound's individual *in vitro* properties, but also presents a potentially appealing approach for scientists to conduct *in vivo* experiments, thereby enhancing our understanding of *in-phase* experiments.

3.2. Techniques and methods

The *in vitro* assay systems utilized in the conduct of CBC studies require different techniques and methods. Spectrophotometric methods have been in use for some time, and there is also much application and knowledge about them^[79,80]. Additionally, methods exist in the fields of chromatographic analyses and molecular assays. These techniques and methods employed hold equal importance to the accuracy and reliability of measurements and values, as analytical methods offer insights into the characteristics and effects of CBCs^[81,82]. Molecular bioassays serve as a foundation in the field of chromatography, facilitating the preparation of CBCs in various areas and applications for both healthy and diseased individuals. *In vitro* studies dedicate a separate section to sample preparation techniques, the most crucial component of laboratory facilities^[83,84]. The preparation processes of CBCs for molecular methods and systems are more difficult than chromatography. The main bottlenecks of spectrophotometric and chromatographic methods are their high minimum detectable levels^[85,86].

The experimental section of all *in vitro* studies, including the aforementioned assays, includes major validation studies. In recent years, researchers have conducted all standard cell culture-related studies under sterile conditions, using tissue culture media at 37°C and 5% CO₂^[87,88]. Laboratory studies primarily undergo processing due to the use of biologically and analytically validated tools in their environments^[89,90]. In coumarin-based research, a comparative analysis of *in vitro* and *in silico* studies highlights the importance of standard and computable conditions.

4. Fundamentals of *in silico* studies

In silico studies, also known as computational ones, are becoming increasingly popular in pharmaceutical research. Computational modeling and simulation are among these studies, enabling the complex interactions at both the biological and chemical levels^[91,92]. Additionally, these studies supplement traditional experimental methods by enhancing our understanding of molecular interactions, biological pathways, and the absorption, distribution, breakdown, excretion, and toxic effects of drugs and other chemicals^[93,94]. One of the major advantages of *in silico* studies is their ability to provide a vast amount of information in a very short period, using a cost-effective and time-efficient approach^[95,96]. Combinatorial chemistry studies design high-throughput experimental procedures to synthesize a large number of compounds. Implementing experimental investigations and assays to synthesize compounds can be both cost-inefficient and time-consuming^[97,98]. *In silico* techniques could potentially alleviate these challenges by objectively selecting compounds that are more likely to have biological effects or exhibit adoptable behaviors^[99,100].

In silico tools are computer-based and can simulate different types of compounds acting in biological pathways. For instance, it is possible to simulate compounds that act as agonists or antagonists, inhibiting or activating enzymes and other biological agents^[101,102]. These tools are capable of performing the aforementioned functions using the structure of compounds as a foundation^[103,104]. Currently, scientists model and simulate these biological effects primarily through statistical models known as quantitative structure-activity relationship (QSAR) models and, more recently, pharmacophore-based methods. Both approaches incorporate diverse methodologies, some of which have proven to yield authentic insights into biological interactions^[105,106].

The development of a variety of *in silico* studies integrated into drug discovery and development—also known as supplementary material—has been made possible by the increasing complexity of computers and the improvement of software dedicated to a wide range of applications^[107,108]. However, over the years,

numerous challenges and limitations have been established because of their complexity, contradictions in software, and availability for systems with different computational resources. It has problems like not being able to use accurate computational methods, using the wrong structural and molecular information to create the *in silico* approach, using the wrong software, the method being too complicated within the software, using the wrong software to predict and describe the effect, not having enough time, and using unethical methods, all of which are debated by researchers^[109,110]. The implementation of more recent *in silico* approaches enhances traditional methodologies in foreign applications and significantly contributes to the scientific decision process in hypothesis generation and screening^[111,112].

4.1. Types of *in silico* studies

The interest in CBCs has increased in the last 10 years due to their variety of biological activities. In the fields of medicinal and food chemistry, there is interest in identifying potential targets of these compounds^[113,114]. *In silico* studies are useful because they allow for the rapid identification of molecular targets and the study of properties of interest in this context. Therefore, the scientific community accepts *in silico* studies as the primary procedural tools for discovering new potential biological CBC properties. Molecular docking, computational chemistry, and pharmacokinetic simulations are the three main methods used in these studies^[115,116].

Computational chemistry is the largest field of *in silico* study. This encompasses two distinct types of predictions: the use of QSAR for studying biological activity and toxicity as well as the application of thermodynamic features to predict the contour of properties^[117]. Finally, pharmacokinetic simulations help understand the fate of a drug within an organism and can predict potential biological activity^[118]. As seen above, *in silico* studies range from a superficial level, such as predicting interactions using molecular docking or virtual screening, to a more in-depth level, evaluating pharmacokinetic and toxicity properties^[119,120]. One key advantage of *in silico* studies is their speed since each *in vitro* and *in vivo* study takes at least one week. Furthermore, these studies can predict experimental results and validate them to some extent. They use current data and all of the model's assumptions, so use them with caution. When possible, analyze the results of *in silico* studies with biological activity as part of the overall research^[121,122].

4.2. Techniques and tools

Today, scientists have access to a myriad of *in silico* software tools that can provide structural predictions and useful thermodynamic data comparable to *in vitro* and clinical studies^[123,124]. The discipline of computational modeling is a versatile topic, combining multiple techniques that pertain to molecular modeling, virtual screening, quantum chemical calculations, and molecular dynamics simulations. Thorough knowledge and experience with the software or algorithm chosen are essential because they could determine how reliable the outcomes of molecular docking, virtual screening, quantum chemical calculations, and molecular dynamics simulations are in the end^[125,126]. Investigational aims, user expertise, and anticipated outcomes regarding CBC interactions with proteins or macromolecules influence the choice of algorithms^[127,128].

Molecular modeling and quantum chemical calculations are crucial in CBC-docking studies. Quantum chemical calculations can help us understand the energies between CBCs and their ligands^[129]. Types of molecular modeling tools may include those for proteins, ligands, and drug design. On the other hand, molecular dynamics tools such as AMBER, GROMACS, CHARMM, NAMD, and LAMMPS can be utilized to perform molecular simulations^[130]. The majority of these are free to use under certain conditions. To simulate molecular dynamics on a receptor structure, *in silico*-induced fit methods require initial preparation and format conversion tools^[131]. As technology and algorithms get better, these methods will benefit the most. New tools are always coming out that give accurate pictures of how CBCs and proteins interact at the molecular level^[132].

Over time, the expansion of available resources has led to the improvement of some commercial and quasi-commercial platforms, enabling the completion of necessary molecular studies in a single location or within a standardized computational workflow^[133]. Over the short term, non-expert users, or those with resource and time constraints, might turn to platforms, software, or hardware that offer simpler and more accurate calculations of CBC interactions. Researchers have also developed newer protocols based on machine learning to create models that can understand how this chemical type interacts with a specific ligand or macromolecule as a drug target^[134]. These models can guess how CBCs bind to small molecules or larger drug or protein structures, what kinds of bioactivity they have, how selective they are, or whether they interact with other proteins^[135].

5. Study considerations

By dividing the benefits, drawbacks, and uses of in vitro and in silico research into two separate parts, **Figure 2** provides a visual comparison of the two. Symbolizing their controlled conditions, cost-effectiveness, and ethical simplicity, the in vitro studies section showcases a laboratory setup with test tubes and a microscope. The in silico studies section, featuring a computer with molecular models and algorithms, serves as an example of computational approaches, their efficiency, and their potential use in drug discovery. To highlight the interdependencies and complementary nature of the three sections' categories, icons and arrows graphically link them. Thanks to the well-organized layout, even the most technical details are simple to grasp.



Figure 2. Comparison of in vitro and in silico studies: Advantages, limitations, and applications.

5.1. Advantages of in vitro studies

Conducting in vitro assays in a controlled environment significantly increases their precision and the accuracy of the quantified results. In comparison to in vivo tests, in vitro studies are simple to perform and do not raise ethical concerns^[136]. Researchers are increasingly focusing on precision medicine and in vitro methods, but they should exercise caution when applying the information from these studies to real-world scenarios^[137]. This is the result of eliminating all complex reactions and processes occurring at the organ and whole-organism levels from the assay; extrapolating outcomes to humans requires direct or indirect in vivo

models^[138]. The relatively low cost and ease of performance make in vitro assays especially applicable to high-throughput screening^[139].

5.2. Limitations of in vitro studies

There are significant limitations in all in vitro assays related directly to the study environment. The microenvironment of the biological system could influence the results from in vitro assays^[140]. These limitations also impact the application of experimental in vitro data to in vivo or clinical situations. Different cells and chemicals in the biological environment are known to react together. The behavior of cells and tissues can facilitate these interactions by modulating the chemical system^[141]. However, in vitro assays typically lack or contain minimal cellular heterogeneity, making it possible to control all conditions at the microenvironment level, unlike in vivo biological settings^[122].

5.3. Advantages of in silico studies

In terms of in silico studies, the use of computational methods broadened our horizon and expanded our capacity to explore the unknown. These methods have yielded benefits such as insightful data analysis and hypothesis generation, which enable the performance and validation of wet laboratory studies^[142]. These methods also use computer programs and tools to make thousands of 3D structures at the atomic level, model the structures of compound-protein complexes, figure out the role of solvents, see how complex compounds behave in protein environments, create energy fields, and quickly check the movement of molecules^[143]. Importantly, they are efficient and more affordable than wet laboratory studies, need no ethical approval for simulations, and simultaneously run in parallel with a few constraints^[144].

5.4. Limitations of in silico studies

The limitations and criticisms surrounding in silico studies have hindered their acceptance and use. These constraints include reliance on input from laboratory or in vitro studies of an analogous target^[145]. Studies also rely on the crystallographic structure, which could potentially lead to bias in the design^[146]. Furthermore, they fundamentally assert that the predictions are undesirable, particularly in the context of ligand-fragment protein docking scenarios^[147]. However, it is also argued that in today's biological world, fully comprehending the system is very hard, and sometimes a precise guess of the active site is the only way to go. Because of this, their reasoning often lacks experimental validation, leading to disagreements^[148].

A major limitation is the accuracy of simulating phenotypes because we do not know everything about biological pathways and complexity. Structure-based functions and protein evolution complicate in silico systems, necessitating the use of appropriate in vitro and in vivo tests to determine their toxicity mechanisms^[149]. Another drawback of these systems studies is the assumptions behind models, and the mechanism of prediction has limitations; it provides indications of the events but not the actual ones, and examination of predictions is also necessary^[150]. Studies from the past have paved the way for efficient predictions of molecular drug design, toxicity studies, and extensions of life sciences with minimum laboratory tests in a short frame of time^[151]. However, the use of computational-based methods escalates the timeline. In general, in silico studies are still useful additions to in vitro and in vivo studies for studying biological targets, molecular mechanisms, predicting ligand binding, and running many simulations^[152].

5.5. Applications of in vitro studies in coumarin-based research

In vitro studies offer a wide range of possible topics for coumarin-based research, ranging from toxicity testing to investigating coumarin-related biomedical effects^[153]. For instance, researchers can evaluate the anticoagulant effect of 4-hydroxycoumarin (**Figure 3**), one of the first CBCs used as a clinical anticoagulant since the 1950s. As a result, researchers introduced crucial in vitro assay systems on liver microsomes to investigate the metabolism of this CBC. Due to their increasing application, these assays are now commercially available not only for hepatocytes but also for endothelial cells and other cells relevant to coumarin-related

research topics^[154]. Today's advancements in generating pluripotent stem cells from nearly every cell in an individual's body, and then producing the necessary cell entities through cell differentiation, have also led to the creation of the first few *in vitro* cell systems^[155] that closely resemble the blood–brain barrier between humans and primates^[156].

The incorporation of additional *in vitro* bioassays into the development of modern drugs and vaccines could potentially reduce the need for *in vivo* research in certain cases^[157]. Conversely, enhancing the use of *in vitro* assay systems might necessitate tight collaboration with disciplinary regulatory offices to prevent financial and time wastage in the event that a drug or vaccine fails to receive approval due to toxic effects not detected by the *in vitro* tests^[158]. Furthermore, studies on the reversibility in the central nervous system of an effect described in *in vitro* studies for a drug such as a CBC may be pivotal. Disregard the naive expectation that *in vitro* activity in liver microsomes must entail a potential risk for a blood coagulation-related side effect; detailed *in vivo* studies must address this^[159]. However, warfarin (**Figure 3**) serves as an excellent model for the necessary translation studies. Despite the racemic warfarin's marked *in vivo* anticoagulant effect, the S-enantiomer exhibits an antagonistic vitamin K action *in vitro*. This knowledge led to the development of an S-warfarin-based rodenticide, which counteracts the *in vivo* warfarin effect when combined with R-warfarin and sold in the market^[160].




Figure 3. The chemical structures of 4-hydroxycoumarin and warfarin exhibit a blue-colored coumarin backbone.

Clearly, *in vivo* investigations are indispensable, and this applies not only to revealing pharmacokinetic profiles but also to the predictive quality of *in vitro* studies, provided results are available. Documenting the lack of predictive quality from *in vitro*-*in vivo* translation is necessary^[161]. Similarly, despite extensive efforts, *in vitro* modeling systems are unable to resolve issues such as variations in drug metabolism and blood clotting patterns among individuals. Moreover, clinical practice can easily address issues of batch and patient heterogeneity, which go beyond influencing studies on the reversibility of an action^[162]. We need to prove such activity both *in vitro* and *in vivo*, and currently, no such studies exist for CBCs. Regrettably, the literature often mistakenly publishes the poorly predictive *in vitro* studies as evidence-based, approved strategies, thereby contributing to its already vast volume.

5.6. Applications of *in silico* studies in coumarin-based research

These studies have strengthened current perceptions and advanced the knowledge of CBCs and their pharmacological potential. Numerous studies have employed the *in silico* approach to forecast the biological activity of these compounds^[163]. Firstly, researchers have utilized numerous molecular docking simulations to identify potential targets for CBCs, with the results potentially aiding in pinpointing precise biological targets^[164]. Not only has the *in silico* approach effectively identified potential targets for networks, but it has also paved the way for the CBC's progression to preclinical and clinical studies. Furthermore, it has blinded analysis of an already identified targets for the compounds under investigation^[165].

Additionally, researchers conducted several *in silico* studies to enhance drug administration, and they used a drug metabolism study to identify the cytochrome P450 enzymes responsible for CBC metabolism^[166]. Another study looked at how human serum albumin and human alpha-1-acid glycoproteins affect the

pharmacokinetic behavior of CBCs, with the goal of improving their bioavailability and effectiveness^[167]. Similarly, scientists used molecular docking and molecular dynamics to study how nitric oxide-CBC prodrugs bind and interact with each other^[168]. Using molecular dynamics in a computer study, researchers looked into the best way to find out how well CBCs fight gliomas by making them more bioavailable across the blood-brain barrier^[169]. However, the computer-aided drug design process limits the use of new drug candidates. Consequently, it is critical to perform *in vitro* and *in vivo* studies to further verify the pharmacological activities of helper CBCs^[170]. Additionally, the computer-aided drug design process has become a significant approach for drug development, with the expectation that it will save time and money, reduce side effects on the intended target, and enhance efficacy compared to existing drugs^[171].

6. Integration of *in vitro* and *in silico* approaches

The integration of two complementary, highly valuable techniques, such as *in vitro* assays and *in silico* approaches, can provide synergies among them. In the case of CBCs, the possibility of integrating both research fields can provide useful information in order to have a comprehensive overview of their biomedical properties, as shown in **Figure 4**. In the early stages of drug discovery, *in silico* studies can predict pharmacokinetic parameters for ADMET characteristics like absorption, distribution, metabolism, excretion, and toxicity^[172]. *In vitro* studies, on the other hand, use real mechanisms to look into one or more of these characteristics. Through collaborative frameworks, *in silico* and *in vitro* researchers have combined to produce pioneering and successful integrative studies^[173]. In some of them, the obtained *in vitro* or *in silico* findings serve as a guide, exclusively supporting and suggesting the experimental or *in silico* approach^[174,175]. Here, we have identified a few integrated research approaches that can optimize and deepen the level of detail, selecting them based on our vision and knowledge of the field. In these examples, the *in silico* approach serves as a guide for designing, predicting, and supporting *in vitro* studies, and vice versa^[172,173,176].




Figure 4. CBCs in the context of integrating *in vitro* and *in silico* techniques.

Interdisciplinary research primarily benefits from the design of new synthetic strategies and the active testing of novel (or already established) CBCs. Above all, the large chemical space under investigation necessitates the use of mechanistic and property predictive methods or tools to minimize costs and time^[177]. Both *in vitro* and *in silico* studies have their limitations; the former approaches lead to potentially time-consuming, costly, and low-throughput research, whereas the predictive capability of *in silico* approaches is strongly dependent on the level of modeling and on the inter-predictability that can be high but not always^[178]. So, combining and adapting new methods would let researchers make the most of the possibilities offered by *in vitro* research while also making toxicological research more reliable and repeatable^[179]. This is why interdisciplinary research would be a new and possibly useful way to do research in the current system.

7. Future directions and emerging technologies

In vitro methods have combined with promising technologies like organ-on-a-chip, microphysiological systems, organoids, and other types of 3D cell cultures in the past few years. These technologies can help reduce the number of animals used in experiments. At the moment, *in silico* methods are also getting better. Quantum mechanics and molecular mechanics calculations let us study how molecules bind, taking into account both the electronic structure and the system's large-scale relaxation. In the future, we expect the integration of artificial intelligence tools, particularly machine learning and computationally driven drug design, to revolutionize *in silico* studies, particularly in virtual high-throughput screening.

Despite the recent technological advances, there are still numerous challenges in routine *in vitro* research that include increasing the efficiency of drug discovery and validation platforms, improving predictive capacity, and enhancing integration with *in silico* research. Integrating compound profiling with other omics data from both *in vitro* and *in vivo* systems could potentially yield more efficient outcomes. To reduce content generation times and costs, it is also beneficial to use other test systems to refine and potentially replace animal experiments. Examples of this could include enhancing the confidence in data to facilitate the creation of more accurate and efficient *in vitro* alternatives. Combining modern high-throughput equipment with automation, robotics, and homogeneous time-resolved fluorescence or immunofluorescence detection methods could have a big effect. Other things that could help are lentiviral transduction, which works with cells that are hard to transfect and can be titrated, and advanced cell cultures like 3D organoids or other 3D cell cultures to make the model more physiologically relevant and useful.

8. Conclusion and summary

This study provides a comparative analysis of coumarin based on both *in vitro* and *in silico* methodologies to inspire future research in this field. We observe that both methodologies have their advantages and limitations and applying them to better understand CBCs requires a clear and balanced perspective. The primary advantages of *in vitro* techniques are that they require minimal prior knowledge, and the results obtained reflect the whole-body effects of the applied dose. The major advantages of *in silico* techniques reside in their valuable time- and cost-saving capabilities and their potential to predict different ramifications, such as toxicity and efficacy. However, a significant drawback of *in silico* techniques is their need for a substantial amount of data and prior information. Furthermore, current these techniques are not capable of simulating the complex enzymatic reactions found in living organisms.

One of the most significant challenges in scientific research is to summarize each and every aspect of a subject matter. This study comprehensively summarizes scientific data related to *in vitro* and *in silico* approaches, revealing insights. Here, we advocate for the preference of new methodologies over *in silico* research or *in vitro* studies, as they offer a more effective and integrative approach. These new, easier, and more convenient ways make it easier for data to flow through many systems and parts of living things. But, computerized and artificial techniques, information technology, spotting opportunities, and better

pharmacokinetic/pharmacodynamic modeling should help us learn more about the pros and cons of CBCs in humans, as well as how safe they are. These new-generation in silico models should guide future in vitro or in vivo research. This study also provides a new comprehensive analysis that emphasizes the advantages and challenges of both in vitro and in silico methodologies in coumarin-based research. We conclude that both methodologies offer synergistic advantages and shortcomings in this research type.

Funding statement: Funding not received for the study.

Consent statement/ethical approval: Not Applicable.

Data availability: Not Applicable.

Conflict of interest

The authors declare that they no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

1. Ahmed F. A current summary of coumarin-based compounds and their therapeutic applications. *Egyptian Journal of Chemistry*. 2024;67(13):1417–37.
2. Mustafa YF, Abdulaziz NT. Biological potentials of hymecromone-based derivatives: A systematic review. *Systematic Reviews in Pharmacy*. 2020;11(11):438–52.
3. Jasim SF, Mustafa YF. Synthesis and Antidiabetic Assessment of New Coumarin-Disubstituted Benzene Conjugates: An In Silico-In Virto Study. *Journal of Medicinal and Chemical Sciences*. 2022;5(6):887–99.
4. Lončar M, Jakovljević M, Šubarić D, Pavlić M, Buzjak Služek V, Cindrić I, Molnar M. Coumarins in Food and Methods of Their Determination. *Foods*. 2020;9(5):645.
5. Mustafa YF, Abdulaziz NT. Hymecromone and its products as cytotoxic candidates for brain cancer : A brief review. *NeuroQuantology*. 2021;19(7):175–86.
6. Hafsan H, Saleh MM, Zabibah RS, Obaid RF, Jabbar HS, Mustafa YF, Sultan MQ, Gabr GA, Ramírez-Coronel AA, Khodadadi M, Dadras M. Dietary Thymol Improved Growth, Body Composition, Digestive Enzyme Activities, Hematology, Immunity, Antioxidant Defense, and Resistance to *Streptococcus iniae* in the Rainbow Trout (*Oncorhynchus mykiss*). El Basuini M, editor. *Aquaculture Nutrition*. 2022;2022:3288139.
7. Mahmood AAJ, Mustafa YF, Abdulstaaar M. New coumarinic azo-derivatives of metoclopramide and diphenhydramine: Synthesis and in vitro testing for cholinesterase inhibitory effect and protection ability against chlorpyrifos. *International Medical Journal Malaysia*. 2014;13(1):3–12.
8. Gupta V, Ambatwar R, Bhanwala N, Khatik GL. Coumarin as a Privileged and Medicinally Important Scaffold in the Treatment of Tuberculosis. *Current Topics in Medicinal Chemistry*. 2023;23(16):1489–502.
9. Mustafa YF. Synthesis, characterization and preliminary cytotoxic study of sinapic acid and its analogues. *Journal of Global Pharma Technology*. 2019;11(9):1–10.
10. Annunziata F, Pinna C, Dallavalle S, Tamborini L, Pinto A. An overview of coumarin as a versatile and readily accessible scaffold with broad-ranging biological activities. *International Journal of Molecular Sciences*. 2020;21(13):1–83.
11. Oglah MK, Mustafa YF. Synthesis, antioxidant, and preliminary antitumor activities of new curcumin analogues. *Journal of Global Pharma Technology*. 2020;12(2):854–62.
12. Mustafa YF. Classical approaches and their creative advances in the synthesis of coumarins: A brief review. *Journal of Medicinal and Chemical Sciences*. 2021;4(6):612–25.
13. Mustafa YF, Najem MA, Tawffiq ZS. Coumarins from Creston apple seeds: Isolation, chemical modification, and cytotoxicity study. *Journal of Applied Pharmaceutical Science*. 2018;8(8):49–56.
14. Zeki NM, Mustafa YF. Natural linear coumarin-heterocyclic conjugates: A review of their roles in phytotherapy. *Fitoterapia*. 2024;175:105929.
15. Mustafa YF, Khalil RR, Mohammed ET. Synthesis and antitumor potential of new 7-halocoumarin-4-acetic acid derivatives. *Egyptian Journal of Chemistry*. 2021;64(7):3711–6.
16. Mustafa YF, Bashir MK, Oglah MK, Khalil RR, Mohammed ET. Bioactivity of some natural and semisynthetic coumarin derived compounds. *NeuroQuantology*. 2021;19(6):129–38.
17. Bashir MK, Mustafa YF, Oglah MK. Synthesis and antitumor activity of new multifunctional coumarins. *Periodico Tche Quimica*. 2020;17(36):871–83.
18. Kim S, Thiessen PA, Cheng T, Yu B, Shoemaker BA, Wang J, Bolton EE, Wang Y, Bryant SH. Literature information in PubChem: associations between PubChem records and scientific articles. *Journal of Cheminformatics*. 2016;8(1):32.

19. Mustafa YF, Khalil RR, Mohammed ET. Antimicrobial activity of aqueous extracts acquired from the seeds of two apples' cultivars. *Systematic Reviews in Pharmacy*. 2020;11(2):382–7.
20. Mustafa YF, Abdulaziza NT, Jasima MH. 4-Methylumbelliferone and its derived compounds: A brief review of their cytotoxicity. *Egyptian Journal of Chemistry*. 2021;64(4):1807–16.
21. Waheed SA, Mustafa YF. Benzocoumarin backbone is a multifunctional and affordable scaffold with a vast scope of biological activities. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):703–21.
22. Jasim SF, Mustafa YF. A Review of Classical and Advanced Methodologies for Benzocoumarin Synthesis. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):676–94.
23. Flores-Morales V, Villasana-Ruiz AP, Garza-Veloz I, González-Delgado S, Martínez-Fierro ML. Therapeutic Effects of Coumarins with Different Substitution Patterns. *Molecules*. 2023;28(5):2413.
24. Hachem K, Jasim SA, Al-Gazally ME, Riadi Y, Yasin G, Turki Jalil A, Abdulkadhm MM, Saleh MM, Fenjan MN, Mustafa YF, Dehno Khalaji A. Adsorption of Pb(II) and Cd(II) by magnetic chitosan-salicylaldehyde Schiff base: Synthesis, characterization, thermal study and antibacterial activity. *Journal of the Chinese Chemical Society*. 2022;69(3):512–21.
25. Pisani L, Catto M, Muncipinto G, Nicolotti O, Carrieri A, Rullo M, Stefanachi A, Leonetti F, Altomare C. A twenty-year journey exploring coumarin-based derivatives as bioactive molecules. *Frontiers in Chemistry*. 2022;10:1002547.
26. Roomi AB, Widjaja G, Savitri D, Jalil AT, Mustafa YF, Thangavelu L, Kazhibayeva G, Suksatan W, Chupradit S, Aravindhan S. SnO₂:Au/Carbon Quantum Dots Nanocomposites: Synthesis, Characterization, and Antibacterial Activity. *Journal of Nanostructures*. 2021;11(3):514–23.
27. Raya I, Chupradit S, Kadhim MM, Mahmoud MZ, Jalil AT, Surendar A, Ghafel ST, Mustafa YF, Bochvar AN. Role of Compositional Changes on Thermal, Magnetic and Mechanical Properties of Fe-P-C-Based Amorphous Alloys. *Chinese Physics B*. 2022;31(1):016401.
28. Fregonezi NF, Aparecida de Souza F, Aleixo NA, Stefany da Silva Gomes P, Silvestre RB, De Grandis RA, Bento da Silva P, Pavan FR, Chorilli M, Resende FA. Cyto-genotoxic evaluation of novel anti-tubercular copper (II) complexes containing isoniazid-based ligands. *Regulatory Toxicology and Pharmacology*. 2020;113:104653.
29. Lesage R, Van Oudheusden M, Schievano S, Van Hoyweghen I, Geris L, Capelli C. Mapping the use of computational modelling and simulation in clinics: A survey. *Frontiers in Medical Technology*. 2023;5:1125524.
30. Cardoso BD, Castanheira EMS, Lanceros-Méndez S, Cardoso VF. Recent Advances on Cell Culture Platforms for In Vitro Drug Screening and Cell Therapies: From Conventional to Microfluidic Strategies. *Advanced Healthcare Materials*. 2023;12(18):e2202936.
31. Chen J, Gu Z, Lai L, Pei J. In silico protein function prediction: the rise of machine learning-based approaches. *Medical Review*. 2023;3(6):487–510.
32. Madorran E, Stožer A, Bevc S, Maver U. In vitro toxicity model: Upgrades to bridge the gap between preclinical and clinical research. *Bosnian Journal of Basic Medical Sciences*. 2020;20(2):157–168.
33. Gheidari D, Mehrdad M, Karimelahi Z. Virtual screening, ADMET prediction, molecular docking, and dynamic simulation studies of natural products as BACE1 inhibitors for the management of Alzheimer's disease. *Scientific Reports*. 2024;14(1):26431.
34. Wang L, Hu D, Xu J, Hu J, Wang Y. Complex in vitro model: A transformative model in drug development and precision medicine. *Clinical and Translational Science*. 2024;17(2):e13695.
35. Chang Y, Hawkins BA, Du JJ, Groundwater PW, Hibbs DE, Lai F. A Guide to In Silico Drug Design. *Pharmaceutics*. 2022;15(1):49.
36. Wright Muelas M, Ortega F, Breitling R, Bendtsen C, Westerhoff H V. Rational cell culture optimization enhances experimental reproducibility in cancer cells. *Scientific Reports*. 2018;8(1):3029.
37. Matzko R, Konur S. Technologies for design-build-test-learn automation and computational modelling across the synthetic biology workflow: a review. *Network Modeling Analysis in Health Informatics and Bioinformatics*. 2024;13(1):22.
38. Zhang C, Sui Y, Liu S, Yang M. In vitro and in vivo experimental models for cancer immunotherapy study. *Current Research in Biotechnology*. 2024;7:100210.
39. Verma SK, Nandi A, Simnani FZ, Singh D, Sinha A, Naser SS, Sahoo J, Lenka SS, Panda PK, Dutt A, Kaushik NK, Singh D, Suar M. In silico nanotoxicology: The computational biology state of art for nanomaterial safety assessments. *Materials & Design*. 2023;235:112452.
40. Kang M, Long T, Chang C, Meng T, Ma H, Li Z, Li P, Chen Y. A Review of the Ethical Use of Animals in Functional Experimental Research in China Based on the "Four R" Principles of Reduction, Replacement, Refinement, and Responsibility. *Medical Science Monitor*. 2022;29:e938807.
41. Gao S, Fang A, Huang Y, Giunchiglia V, Noori A, Schwarz JR, Ektefaie Y, Kondic J, Zitnik M. Empowering biomedical discovery with AI agents. *Cell*. 2024;187(22):6125–51.
42. Petrucciani A, Hoerter A, Kotze L, Du Plessis N, Pienaar E. In silico agent-based modeling approach to characterize multiple in vitro tuberculosis infection models. Puniya BL, editor. *PLOS ONE*. 2024;19(3):e0299107.
43. Shi D, Mi G, Wang M, Webster TJ. In vitro and ex vivo systems at the forefront of infection modeling and drug discovery. *Biomaterials*. 2019;198:228–49.

44. Xu H, Qin J, Qin L, Guo C, Yang B. Bioinformatics and In Silico Findings Uncover Bio-Targets of Calycosin Against Heart Failure and Diabetes Mellitus. *Frontiers in Endocrinology*. 2022;13:790619.
45. Danchin A. In vivo , in vitro and in silico : an open space for the development of microbe-based applications of synthetic biology. *Microbial Biotechnology*. 2022;15(1):42–64.
46. Agamah FE, Mazandu GK, Hassan R, Bope CD, Thomford NE, Ghansah A, Chimusa ER. Computational/in silico methods in drug target and lead prediction. *Briefings in Bioinformatics*. 2020;21(5):1663–75.
47. Grossmann I, Rotella A, Hutcherson CA, Sharpinskyi K, Varnum MEW, Achter S, Dhami MK, Guo XE, Kara-Yakoubian M, Mandel DR, Raes L, Tay L, Vie A, Wagner L, Adamkovic M, Arami A, Arriaga P, Bandara K, et al. Insights into the accuracy of social scientists' forecasts of societal change. *Nature Human Behaviour*. 2023;7:484–501.
48. Mustafa YF. Harmful Free Radicals in Aging: A Narrative Review of Their Detrimental Effects on Health. *Indian Journal of Clinical Biochemistry*. 2024;39(2):154–67.
49. Upchurch WJ, Iaizzo PA. In vitro contractile studies within isolated tissue baths: Translational research from Visible Heart® Laboratories. *Experimental Biology and Medicine*. 2022;247(7):584–97.
50. Jebir RM, Mustafa YF. Watermelon Allsweet: A promising natural source of bioactive products. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):652–66.
51. Mustafa YF, Mohammed NA alwahab. A promising oral 5-fluorouracil prodrug for lung tumor: Synthesis, characterization and release. *Biochemical and Cellular Archives*. 2021;21(Supp 1):1991–9.
52. Huldani H, Rashid AI, Turaev KN, Oplencia MJC, Abdelbasset WK, Bokov DO, Mustafa YF, Al-Gazally ME, Hammid AT, Kadhim MM, Ahmadi SH. Concanavalin A as a promising lectin-based anti-cancer agent: the molecular mechanisms and therapeutic potential. *Cell Communication and Signaling*. 2022;20(1):1–14.
53. Khalil RR, Mohammed ET, Mustafa YF. Evaluation of in vitro antioxidant and antidiabetic properties of *Cydonia Oblonga* seeds' extracts. *Journal of Medicinal and Chemical Sciences*. 2022;5(6):1048–58.
54. Rohmah MK, Salahdin OD, Gupta R, Muzammil K, Qasim MT, Al-qaim ZH, Abbas NF, Jawad MA, Yasin G, Mustafa YF, Heidary A, Abarghouei S. Modulatory role of dietary curcumin and resveratrol on growth performance, serum immunity responses, mucus enzymes activity, antioxidant capacity and serum and mucus biochemicals in the common carp, *Cyprinus carpio* exposed to abamectin. *Fish and Shellfish Immunology*. 2022;129:221–30.
55. Hirsch C, Schildknecht S. In Vitro Research Reproducibility: Keeping Up High Standards. *Frontiers in Pharmacology*. 2019;10:1484.
56. Setia Budi H, Javed Ansari M, Abdalkareem Jasim S, Abdelbasset WK, Bokov D, Fakri Mustafa Y, Najm MAA, Kazemnejadi M. Preparation of antibacterial Gel/PCL nanofibers reinforced by dicalcium phosphate-modified graphene oxide with control release of clindamycin for possible application in bone tissue engineering. *Inorganic Chemistry Communications*. 2022;139:109336.
57. Mustafa YF, Ismael RN, Jebir RM. Natural coumarins from two cultivars of watermelon seeds as biosafe anticancer agents, an algorithm for their isolation and evaluation. *Journal of Molecular Structure*. 2024;1295(P1):136644.
58. Budi HS, Younus LA, Lafta MH, Parveen S, Mohammad HJ, Al-qaim ZH, Jawad MA, Parra RMR, Mustafa YF, Alhachami FR, Karampoor S, Mirzaei R. The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy. *Frontiers in Oncology*. 2023;12:1067974.
59. Dantas RF, Evangelista TCS, Neves BJ, Senger MR, Andrade CH, Ferreira SB, Silva-Junior FP. Dealing with frequent hitters in drug discovery: a multidisciplinary view on the issue of filtering compounds on biological screenings. *Expert Opinion on Drug Discovery*. 2019;14(12):1269–82.
60. Abdulaziz NT, Mustafa YF. Antibacterial and Antitumor Potentials of Some Novel Coumarins. *International Journal of Drug Delivery Technology*. 2022;12(1):239–47.
61. Mustafa YF, Zain Al-Abdeen SH, Khalil RR, Mohammed ET. Novel functionalized phenyl acetate derivatives of benzo [e]-bispyrone fused hybrids: Synthesis and biological activities. *Results in Chemistry*. 2023;5:100942.
62. Budi HS, Jameel MF, Widjaja G, Alasady MS, Mahmudiono T, Mustafa YF, Fardeeva I, Kuznetsova M. Study on the role of nano antibacterial materials in orthodontics (a review). *Brazilian Journal of Biology*. 2024;84(e257070):1–7.
63. Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, Qin S. Cytochrome P450 Enzymes and Drug Metabolism in Humans. *International Journal of Molecular Sciences*. 2021;22(23):12808.
64. Khalil RR, Mohammed ET, Mustafa YF. Various promising biological effects of Cranberry extract: A review. *Clinical Schizophrenia and Related Psychoses*. 2021;15(S6):1–9.
65. Mustafa YF, Oglah MK, Bashir MK. Conjugation of sinapic acid analogues with 5- Fluorouracil: Synthesis, preliminary cytotoxicity, and release study. *Systematic Reviews in Pharmacy*. 2020;11(3):482–9.
66. Waheed SA, Mustafa YF. Novel naphthalene-derived coumarin composites: synthesis, antibacterial, and antifungal activity assessments. *Eurasian Chemical Communications*. 2022;4(8):709–24.
67. Foroozesh M, Sridhar J, Goyal N, Liu J. Coumarins and P450s, Studies Reported to-Date. *Molecules*. 2019;24(8):1620.
68. Ismael RN, Mustafa YF, Al-qazaz HK. *Citrullus lanatus*, a Potential Source of Medicinal Products : A Review. *Journal of Medicinal and Chemical Sciences*. 2022;5(4):607–18.

69. Jasim SF, Mustafa YF. Synthesis, ADME Study, and antimicrobial evaluation of novel naphthalene-based derivatives. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):793–807.
70. Jasim SF, Mustafa YF. New fused-coumarin composites: Synthesis, anticancer and antioxidant potentials evaluation. *Eurasian Chemical Communications*. 2022;4(7):607–19.
71. Lee J, Beers JL, Geffert RM, Jackson KD. A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment. *Biomolecules*. 2024;14(1):99.
72. Ismael RN, Mustafa YF, Al-Qazaz HK. Cancer-curative potential of novel coumarins from watermelon princess: A scenario of their isolation and activity. *Eurasian Chemical Communications*. 2022;4(7):657–72.
73. Kim Y, Bae S, Chung WK, Kwon J, Song I, Lee S. Exploration of pharmacokinetic differences between East Asians and Caucasians: insights from pharmacokinetic studies in healthy subjects. *Translational and Clinical Pharmacology*. 2024;32(3):127.
74. Kasim SM, Abdulaziz NT, Jasim MH, Mustafa YF. Resveratrol in cancer chemotherapy: Is it a preventer, protector, or fighter? *Eurasian Chemical Communications*. 2023;5(7):576–87.
75. Bashir MK, Mustafa YF, Oglah MK. Antitumor, antioxidant, and antibacterial activities of glycosyl-conjugated compounds: A review. *Systematic Reviews in Pharmacy*. 2020;11(4):175–87.
76. Maashi MS, Al-Mualm M, Al-Awsi GRL, Opulencia MJC, Al-Gazally ME, Abdullaev B, Abdelbasset WK, Ansari MJ, Jalil AT, Alsaikhan F, Shalaby MN, Mustafa YF. Apigenin alleviates resistance to doxorubicin in breast cancer cells by acting on the JAK/STAT signaling pathway. *Molecular Biology Reports*. 2022;49:8777–84.
77. Ahmed ME salato AE naby. In vitro propagation and improving accumulation of coumarin in *Lycium barbarum*, a rare plant in the flora of Egypt. *Bulletin of the National Research Centre*. 2022;46(1):220.
78. Kasim SM, Al-Dabbagh BM, Mustafa YF. A review on the biological potentials of carbazole and its derived products. *Eurasian Chemical Communications*. 2022;4(6):495–512.
79. Aldewachi H, Mustafa YF, Najm R, Ammar F. Adulteration of Slimming Products and its Detection Methods. *Systematic Reviews in Pharmacy*. 2020;11(3):289–96.
80. Abdulaziz NT, Mustafa YF. The Effect of Heat Variable on the Chemical Composition and Bioactivities of a *Citrullus lanatus* Seed Aqueous Extracts. *Journal of Medicinal and Chemical Sciences*. 2022;5(7):1166–76.
81. Almeida CMM. Overview of Sample Preparation and Chromatographic Methods to Analysis Pharmaceutical Active Compounds in Waters Matrices. *Separations*. 2021;8(2):16.
82. Waheed SA, Mustafa YF. The in vitro effects of new albocarbon-based coumarins on blood glucose-controlling enzymes. *Journal of Medicinal and Chemical Sciences*. 2022;5(6):954–67.
83. Habibi W, Talbi S, Hamri S, Hafid A, Khouili M. Coumarin Derivatives: Microwave Synthesis and Biological Properties—A Review. *Journal of Heterocyclic Chemistry*. 2024;61(12):2070–96.
84. Ahmed BA, Mustafa YF, Ibrahim BY. Isolation and characterization of furanocoumarins from Golden Delicious apple seeds. *J Med Chem Sci*. 2022;5:537–45.
85. Mustafa YF. Triple coumarin-based 5-fluorouracil prodrugs, their synthesis, characterization, and release kinetics. *Journal of Molecular Structure*. 2024;1301:137415.
86. Al-Shakarchi W, Abdulaziz NT, Mustafa YF. A review of the chemical, pharmacokinetic, and pharmacological aspects of quercetin. *Eurasian Chemical Communications*. 2022;4(7):645–56.
87. Mustafa YF, Mohammed ET, Khalil RR. Antioxidant and antitumor activities of methanolic extracts obtained from Red Delicious and Granny Smith apples' seeds. *Systematic Reviews in Pharmacy*. 2020;11(4):570–6.
88. Hjazi A, Nasir F, Noor R, Alsalamy A, Zabibah RS, Romero-Parra RM, Ullah MI, Mustafa YF, Qasim MT, Akram SV. The pathological role of C-X-C chemokine receptor type 4 (CXCR4) in colorectal cancer (CRC) progression; special focus on molecular mechanisms and possible therapeutics. *Pathology - Research and Practice*. 2023;248:154616.
89. Mattarozzi M, Laski E, Bertucci A, Giannetto M, Bianchi F, Zoani C, Careri M. Metrological traceability in process analytical technologies and point-of-need technologies for food safety and quality control: not a straightforward issue. *Analytical and Bioanalytical Chemistry*. 2023;415(1):119–35.
90. Al Abdeen SHZ, Mustafa YF, Mutlag SH. Synthesis and biomedical activities of novel multifunctional benzodipyronone-based derivatives. *Eurasian Chemical Communications*. 2022;4(10):938–49.
91. Sadybekov A V., Katritch V. Computational approaches streamlining drug discovery. *Nature*. 2023;616(7958):673–85.
92. Mustafa YF, Bashir MK, Oglah MK. Influence of albocarbon-cyclic hybridization on biomedical activities: A review. *Journal of Medicinal and Chemical Sciences*. 2022;5(4):518–35.
93. Firoozeh AZ, Bokov DO, Salahdin OD, Abdelbasset WK, Jawad MA, Kadhi MM, Qasim MT, Kzar HH, Al-Gazally ME, Mustafa YF, Khatami M. Cytotoxicity evaluation of environmentally friendly synthesis Copper/Zinc bimetallic nanoparticles on MCF-7 cancer cells. *Rendiconti Lincei Scienze Fisiche e Naturali*. 2022;33:441–7.
94. Jebir MR, Mustafa YF. Kidney stones: natural remedies and lifestyle modifications to alleviate their burden. *International Urology and Nephrology*. 2024;56(3):1025–33.
95. Mushebenge AGA, Ugbaja SC, Mbatha NA, B. Khan R, Kumalo HM. Assessing the Potential Contribution of In Silico Studies in Discovering Drug Candidates That Interact with Various SARS-CoV-2 Receptors. *International Journal of Molecular Sciences*. 2023;24(21):15518.

96. Hammoodi SH, Ismael SS, Mustafa YF. Mutual prodrugs for colon targeting: A review. *Eurasian Chemical Communications*. 2022;4(12):1251–65.
97. Chen Z, Lu D, Cao J, Zhao F, Feng G, Xu C, Deng Y, Xiang X -D. Development of high-throughput wet-chemical synthesis techniques for material research. *Materials Genome Engineering Advances*. 2023;1(1):e5.
98. Mustafa YF. Effects of heat variables on the starch content of cooked white rice: Searching for diabetes-friendly food. *Bioactive Carbohydrates and Dietary Fibre*. 2024;31:100395.
99. Mustafa YF. Coumarins from carcinogenic phenol: synthesis, characterization, in silico, biosafety, anticancer, antioxidant, and anti-inflammatory assessments. *Chemical Papers*. 2024;78:493–504.
100. Ismael SS, Waheed NAM, Kasim SM, Mustafa YF. Novel Coumarin-Indole Hybrids as Cytotoxic Candidates: Synthesis and Antiproliferative Activity. *Pharmacognosy Journal*. 2023;15(6):1105–11.
101. Bruno A, Costantino G, Sartori L, Radi M. The In Silico Drug Discovery Toolbox: Applications in Lead Discovery and Optimization. *Current Medicinal Chemistry*. 2019;26(21):3838–73.
102. Younes HA, Mustafa YF. Sweet Bell Pepper: A Focus on Its Nutritional Qualities and Illness-Alleviated Properties. *Indian Journal of Clinical Biochemistry*. 2024;39:459–69.
103. Mustafa YF. Synthesis, in silico analysis, and biomedical effects of coumarins derived from resveratrol. *Phytomedicine Plus*. 2024;3(4):100501.
104. Al Abdeen SHZ, Mustafa YF, Mutlag SH. Synthesis of disubstituted anisolodipyronederived ester compounds: The search for new bioactive candidates. *Eurasian Chemical Communications*. 2022;4(11):1171–83.
105. Kohlbacher SM, Langer T, Seidel T. QPHAR: quantitative pharmacophore activity relationship: method and validation. *Journal of Cheminformatics*. 2021;13(1):57.
106. Younes AH, Mustafa YF. Plant-Derived Coumarins: A Narrative Review Of Their Structural And Biomedical Diversity. *Chemistry & Biodiversity*. 2024;21(6):e202400344.
107. Al-Mohaya M, Mesut B, Kurt A, Çelik YS. In silico approaches which are used in pharmacy. *Journal of Applied Pharmaceutical Science*. 2024;14(4):239–253.
108. Mustafa YF, Bashir MK, Oglah MK. Synthesis, antioxidant and antitumor activities of new coumarins grafted to 5-fluorouracil. *Caspian Journal of Environmental Sciences*. 2022;20(2):359–65.
109. Silva CAG da, Ramos FN, de Moraes RV, Santos EL dos. ChatGPT: Challenges and Benefits in Software Programming for Higher Education. *Sustainability*. 2024;16(3):1245.
110. Mustafa YF, Abdulaziz NT. Anticancer potential of hymecromone-based compounds: A review. *Biochemical and Cellular Archives*. 2021;21(2):4151–61.
111. Cattaneo I, Astuto MC, Binaglia M, Devos Y, Dorne JLCM, Fernandez Agudo A, Fernandez Dumont A, Garcia-Vello P, Kass GEN, Lanzoni A, Liem AKD, Panzarea M, Paraskevopoulos K, Parra Morte JM, Tarazona J V., Terron A. Implementing New Approach Methodologies (NAMs) in food safety assessments: Strategic objectives and actions taken by the European Food Safety Authority. *Trends in Food Science & Technology*. 2023;133:277–90.
112. Abdulaziz NT, Mohammed ET, Khalil RR, Mustafa YF. Unrevealing the total phenols, total flavonoids, antioxidant, anti-inflammatory, and cytotoxic effects of Garden Cress seed ethanolic extracts. *Review of Clinical Pharmacology and Pharmacokinetics - International Edition*. 2024;38(2):187–96.
113. Mustafa YF. Emerging trends and future opportunities for coumarin-heterocycle conjugates as antibacterial agents. *Results in Chemistry*. 2023;6:101151.
114. Ban AA, Ibrahim BY, Mustafa YF. The Protective Role of Natural Coumarins Derivatives and Anpro Supplement Against Aflatoxin B1 Pollution in the Quails Coturnix Japonica Diet. *Mesopotamia Journal of Agriculture*. 2023;51(1):1–13.
115. Fatoki TH, Balogun TC, Ojewuyi AE, Omole AC, Olukayode OV, Adewumi AP, Umesi AJ, Ijeoma NP, Apooyin AE, Chinedu CP, Idowu IE, Isah MJ. In silico molecular targets, docking, dynamics simulation and physiologically based pharmacokinetics modeling of oritavancin. *BMC Pharmacology and Toxicology*. 2024;25(1):79.
116. Jibroo RN, Mustafa YF, Al-Shakarchi W. Heterocycles fused on a 6,7-coumarin framework: an in-depth review of their structural and pharmacological diversity. *Chemical Papers*. 2024;78:7239–7311.
117. Zeki NM, Mustafa YF. Digital alchemy: Exploring the pharmacokinetic and toxicity profiles of selected coumarin-heterocycle hybrids. *Results in Chemistry*. 2024;10:101754.
118. Mustafa YF. Biocompatible chlorocoumarins from harmful chlorophenols, their synthesis and biomedical evaluation. *Journal of Molecular Structure*. 2024;1309:138193.
119. Mustafaa YF. New Coumarin-Metronidazole Composites: Synthesis, Biocompatibility, and Anti-anaerobic Bacterial Activity. *Russian Journal of Bioorganic Chemistry*. 2024;50(1):201–10.
120. Mustafa YF, Faisal AF, Alshaher MM, Hassan DA. Food-Derived Micronutrients as Alleviators of Age-Related Dysfunction: A Dive into Their Effects and Cellular Mechanisms. *Indian Journal of Clinical Biochemistry*. 2025; <https://doi.org/10.1007/s12291-024-01297-7>
121. Correia C, Ferreira A, Santos J, Lapa R, Yliperttula M, Urtti A, Vale N. New In Vitro-In Silico Approach for the Prediction of In Vivo Performance of Drug Combinations. *Molecules*. 2021;26(14):4257.
122. Mustafa YF. Coumarins from toxic phenol: An algorithm of their synthesis and assessment as biosafe, wide-spectrum, potent antimicrobial prospects. *Applied Chemical Engineering*. 2024;7(3):5527.

123. Fasano C, Lepore Signorile M, De Marco K, Forte G, Disciglio V, Sanese P, Grossi V, Simone C. In Silico Deciphering of the Potential Impact of Variants of Uncertain Significance in Hereditary Colorectal Cancer Syndromes. *Cells*. 2024;13(16):1314.
124. Alshaher MM, Mustafa YF. Synthesis of triclosan-derived coumarins as potent, biocompatible, broad-spectrum antimicrobial agents. *Applied Chemical Engineering*. 2024;7(4):5579.
125. Lin X, Li X, Lin X. A Review on Applications of Computational Methods in Drug Screening and Design. *Molecules*. 2020;25(6):1375.
126. Mustafa YF, Hassan DA. Dioxolocoumarins: Bridging chemistry and pharmacology with multifunctional therapeutics. *Applied Chemical Engineering*. 2024;7(4):5592.
127. Zeki MN, Mustafa YF. Synthesis and evaluation of novel ring-conjugated coumarins as biosafe broad-spectrum antimicrobial candidates. *Journal of Molecular Structure*. 2024;1309:138192.
128. Faisal AF, Mustafa YF. The role of coumarin scaffold in the chemical engineering of bioactive molecules: A narrative review. *Applied Chemical Engineering*. 2025;8(1):5595.
129. Mustafa YF. Synthesis of 7,8-dihydroxy-4-phenylbenzo[g]coumarins as potential multitarget anti-skin-aging candidates. *Journal of Molecular Structure*. 2025;1321:139806.
130. Mustafa YF. Synthesis of novel 6-aminocoumarin derivatives as potential –biocompatible antimicrobial and anticancer agents. *Journal of Molecular Structure*. 2025;1320:139658.
131. Mustafa YF. 3-mercaptocoumarins as potential bioactive candidates: From novel synthesis to comparative analysis. *Journal of Molecular Structure*. 2025;1320:139657.
132. Mustafa YF, Hassan DA, Faisal AF, Alshaher MM. Synthesis of novel skipped diene-3-halocoumarin conjugates as potent anticancer and antibacterial biocompatible agents. *Results in Chemistry*. 2024;11:101846.
133. Laycock BG, Chan CM, Halley PJ. A review of computational approaches used in the modelling, design, and manufacturing of biodegradable and biobased polymers. *Progress in Polymer Science*. 2024;157:101874.
134. Çubukçu HC, Topcu Dİ, Yenice S. Machine learning-based clinical decision support using laboratory data. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2024;62(5):793–823.
135. Hussein HK, Aubead NM, Kzar HH, Karim YS, Amin AH, Al-Gazally ME, Ahmed TI, Jawad MA, Hammid AT, Jalil AT, Mustafa YF, Saleh MM, Heydari H. Association of cord blood asprosin concentration with atherogenic lipid profile and anthropometric indices. *Diabetology & Metabolic Syndrome*. 2022;14(1):74.
136. Mohammed ET, Khalil RR, Mustafa YF. Phytochemical Analysis and Antimicrobial Evaluation of Quince Seeds' Extracts. *Journal of Medicinal and Chemical Sciences*. 2022;5(6):968–79.
137. Nejres AM, Ali HK, Behnam SP, Mustafa YF. Potential effect of ammonium chloride on the optical physical properties of polyvinyl alcohol. *Systematic Reviews in Pharmacy*. 2020;11(6):726–32.
138. Jebir RM, Mustafa YF. Novel coumarins isolated from the seeds of *Citrullus lanatus* as potential antimicrobial agents. *Eurasian Chemical Communications*. 2022;4(8):692–708.
139. Doyle SE, Cazzola CN, Coleman CM. Design considerations when creating a high throughput screen-compatible in vitro model of osteogenesis. *SLAS Discovery*. 2024;29(7):100184.
140. Cometta S, Hutmacher DW, Chai L. In vitro models for studying implant-associated biofilms - A review from the perspective of bioengineering 3D microenvironments. *Biomaterials*. 2024;309:122578.
141. Jebir RM, Mustafa YF. Natural products catalog of allsweet watermelon seeds and evaluation of their novel coumarins as antimicrobial candidates. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):831–47.
142. Son A, Park J, Kim W, Lee W, Yoon Y, Ji J, Kim H. Integrating Computational Design and Experimental Approaches for Next-Generation Biologics. *Biomolecules*. 2024;14(9):1073.
143. Adiyaman R, McGuffin LJ. Methods for the Refinement of Protein Structure 3D Models. *International Journal of Molecular Sciences*. 2019;20(9):2301.
144. Zeki NM, Mustafa YF. Coumarin hybrids: a sighting of their roles in drug targeting. *Chemical Papers*. 2024;78:5753–5772.
145. Pastorino P, Prearo M, Barceló D. Ethical principles and scientific advancements: In vitro, in silico, and non-vertebrate animal approaches for a green ecotoxicology. *Green Analytical Chemistry*. 2024;8:100096.
146. Zhu Q, Hattori S. Organic crystal structure prediction and its application to materials design. *Journal of Materials Research*. 2023;38(1):19–36.
147. Younes AH, Mustafa YF. Unveiling the Biomedical Applications of Novel Coumarins Isolated From *Capsicum Annuum* L. Seeds by a Multivariate Extraction Technique. *Chemistry and Biodiversity*. 2024;21(6):e202400581.
148. Younes AH, Mustafa YF. Novel coumarins from green sweet bell pepper seeds: Their isolation, characterization, oxidative stress-mitigating, anticancer, anti-inflammatory, and antidiabetic properties. *Journal of Molecular Structure*. 2024;1312:138629.
149. Yubero P, Lavin AA, Poyatos JF. The limitations of phenotype prediction in metabolism. Cannon W, editor. *PLOS Computational Biology*. 2023;19(11):e1011631.
150. Mustafa YF. Nutraceutical-based telomerase inhibitors: Renewed hope for cancer therapy. *Phytomedicine Plus*. 2024;4(2):100537.
151. Mustafa YF. 4-Chloroskimmetine-based derivatives as potential anticancer and antibacterial prospects: Their synthesis and in vitro inspections. *Results in Chemistry*. 2024;7:101511.

152. Pappalardo M, Sipala FM, Nicolosi MC, Guccione S, Ronsisvalle S. Recent Applications of In Silico Approaches for Studying Receptor Mutations Associated with Human Pathologies. *Molecules*. 2024;29(22):5349.
153. Zeki NM, Mustafa YF. Novel heterocyclic coumarin annulates: synthesis and figuring their roles in biomedicine, bench-to-bedside investigation. *Chemical Papers*. 2024;78:4935–51.
154. Some Experimental Studies on the Anticoagulant Activity of the Synthetic Coumarin Derivatives. *Jordan Journal of Biological Sciences*. 2022;15(04):643–7.
155. Ghasemi Darestani N, Gilmanova AI, Al-Gazally ME, Zekiy AO, Ansari MJ, Zabibah RS, Jawad MA, Al-Shalah SAJ, Rizaev JA, Alnassar YS, Mohammed NM, Mustafa YF, Darvishi M, Akhavan-Sigari R. Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment. *Cell Communication and Signaling*. 2023;21(1):43.
156. Mustafa YF. Chemotherapeutic applications of folate prodrugs: A review. *NeuroQuantology*. 2021;19(8):99–112.
157. Zamanian MY, Parra RMR, Soltani A, Kujawska M, Mustafa YF, Raheem G, Al-Awsi L, Lafta HA, Taheri N, Heidari M, Golmohammadi M, Bazmandegan G. Targeting Nrf2 signaling pathway and oxidative stress by resveratrol for Parkinson's disease: an overview and update on new developments. *Molecular Biology Reports*. 2023;50:5455–5464.
158. Waheed SA, Mustafa YF. Synthesis and evaluation of new coumarins as antitumor and antioxidant applicants. *Journal of Medicinal and Chemical Sciences*. 2022;5(5):808–19.
159. Abdulaziz NT, Al-bazzaz FY, Mustafa YF. Natural products for attenuating Alzheimer's disease: A narrative review. *Eurasian Chemical Communications*. 2023;5(4):358–70.
160. Bala MM, Celinska-Lowenhoff M, Szot W, Padjas A, Kaczmarczyk M, Swierz MJ, Undas A. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome. *Cochrane Database of Systematic Reviews*. 2020;2020(10):CD012169.
161. Murata Y, Neuhoff S, Rostami-Hodjegan A, Takita H, Al-Majdoub ZM, Ogungbenro K. In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition. *The AAPS Journal*. 2022;24(1):28.
162. Singh AV, Chandrasekar V, Paudel N, Laux P, Luch A, Gemmati D, Tisato V, Prabhu KS, Uddin S, Dakua SP. Integrative toxicogenomics: Advancing precision medicine and toxicology through artificial intelligence and OMICs technology. *Biomedicine & Pharmacotherapy*. 2023;163:114784.
163. Mustafa YF. Combretastatin A4-based coumarins: synthesis, anticancer, oxidative stress-relieving, anti-inflammatory, biosafety, and in silico analysis. *Chemical Papers*. 2024;78:3705–3720.
164. Zeki NM, Mustafa YF. 6,7-Coumarin-heterocyclic hybrids: A comprehensive review of their natural sources, synthetic approaches, and bioactivity. *Journal of Molecular Structure*. 2024;1303:137601.
165. Gomes AFT, de Medeiros WF, Medeiros I, Piuvezam G, da Silva-Maia JK, Bezerra IWL, Morais AH de A. In Silico Screening of Therapeutic Targets as a Tool to Optimize the Development of Drugs and Nutraceuticals in the Treatment of Diabetes mellitus: A Systematic Review. *International Journal of Molecular Sciences*. 2024;25(17):9213.
166. Hossam Abdelmonem B, Abdelaal NM, Anwer EKE, Rashwan AA, Hussein MA, Ahmed YF, Khashana R, Hanna MM, Abdelnaser A. Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review. *Biomedicines*. 2024;12(7):1467.
167. McNamara PJ, Meiman D. Predicting Drug Binding to Human Serum Albumin and Alpha One Acid Glycoprotein in Diseased and Age Patient Populations. *Journal of Pharmaceutical Sciences*. 2019;108(8):2737–47.
168. Shahpouri P, Mehralitabar H, Kheirabadi M, Kazemi Nourini S. Potential suppression of multidrug-resistance-associated protein 1 by coumarin derivatives: an insight from molecular docking and MD simulation studies. *Journal of Biomolecular Structure and Dynamics*. 2024;42(17):9184–200.
169. Tincu (Iurciuc) CE, Andrițoiu CV, Popa M, Ochiuz L. Recent Advancements and Strategies for Overcoming the Blood–Brain Barrier Using Albumin-Based Drug Delivery Systems to Treat Brain Cancer, with a Focus on Glioblastoma. *Polymers*. 2023;15(19):3969.
170. Zeki NM, Mustafa YF. Annulated Heterocyclic[g]Coumarin Composites: Synthetic Approaches and Bioactive Profiling. *Chemistry and Biodiversity*. 2024;21(3):e202301855.
171. Zeki NM, Mustafa YF. Coumarin hybrids for targeted therapies: A promising approach for potential drug candidates. *Phytochemistry Letters*. 2024;60:117–33.
172. Mustafa YF. Coumarins derived from natural methoxystilbene as oxidative stress-related disease alleviators: Synthesis and in vitro-in silico study. *Journal of Molecular Structure*. 2024;1302:137471.
173. Jibroo RN, Mustafa YF, Al-Shakarchi W. Synthesis and evaluation of linearly fused thiazolocoumarins as prospects with broad-spectrum bioactivity. *Results in Chemistry*. 2024;7:101494.
174. Faisal AF, Mustafa YF. Chili pepper: A delve into its nutritional values and roles in food-based therapy. *Food Chemistry Advances*. 2025;6:100928.
175. Faisal AF, Mustafa YF. The Multifaceted Chemistry of Chili Peppers: A Biodiversity Treasure for Nutrition and Biomedicine. *Chemistry & Biodiversity*. 2025; <https://doi.org/10.1002/cbdv.202402690>
176. Zeki NM, Mustafa YF. Synthesis of Novel Dioxathiole-6,7-coumarin Hybrids As Cytosafe-Multifunctional Applicants: An In Vitro—In Silico Study. *Russian Journal of Bioorganic Chemistry*. 2024;50(5):2076–91.

177. Oprea TI, Weininger D. Rethinking Medicinal Chemistry in the Cheminformatics Age. *Journal of Medicinal Chemistry*. 2024;67(20):17935–9.
178. Jibroo RN, Mustafa YF. Linearly ring-fused coumarins: A review of their cancer-fighting attributes. *Results in Chemistry*. 2024;8:101611.
179. Jasim MHM, Mustafa YF. Synthesis of Acetaminophen-Based Coumarins as Selective COX-2 Inhibitors: An in vitro-in silico Study. *Chemistry & Biodiversity*. 2024;21(10):e202401309.